NKNaruaki Kawasaki

Naruaki Kawasaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Naruaki Kawasaki has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Feasibility of a randomised controlled trial comparing opioid dose escalation with low-dose methadone addition for refractory cancer pain: JORTC-PAL23/NCCH2309 – protocol

    by Takako Ikegami, Rumi Nishimura, Kosuke Terada, Shunsuke Oyamada, Keisuke Ariyoshi, Ayana Hirose, Naho Matsubara, Ayaka Ishikawa, Naruaki Kawasaki, Sayaka Arakawa, et al.

    Introduction: Methadone exerts analgesic effects through μ-opioid receptor affinity and N-methyl-D-aspartate receptor antagonism, which may benefit refractory cancer pain with neuropathic components. Methadone can be introduced by the ‘stop-and-go’ (SAG) method or the ‘add-on’ (AO) method, in which low-dose methadone is added to existing opioids. Observational studies suggest AO may improve pain control but no double-blind randomised controlled trial (RCT) has evaluated this approach. Therefore, the primary aim of this study is to assess the feasibility of conducting a double-blind RCT comparing methadone AO therapy with opioid dose escalation according to standard practice for refractory cancer pain while also exploring safety and preliminary efficacy signals. Methods and analysis: A two-centre, randomised, double-blind, two-arm feasibility trial will enrol 22 patients with advanced or recurrent cancer and inadequately controlled pain (oral morphine equivalent daily dose 60–300 mg). Participants will be allocated 1:1 to the methadone AO or opioid-escalation group using a web-based randomisation system with the minimisation method. The primary endpoint is the completion rate of the 2-week study treatment. Secondary outcomes include pain intensity (Brief Pain Inventory), time to adequate pain control, achievement of a personalised pain goal, adverse events (Common Terminology Criteria for Adverse Events (CTCAE)/Patient-Reported Outcomes version of the CTCAE) and quality of life (European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire Core 15-PAL). Feasibility will be determined based on achieving a treatment completion rate of 70% or higher. Ethics and dissemination: The protocol was approved by the Certified Review Board of the National Cancer Centre Hospital (CRB3180008). Written informed consent will be obtained from all participants. The trial is registered in the Japan Registry of Clinical Trials. Results will be published in peer-reviewed journals and presented at international conferences. Trial registration number: jRCTs031240220.

  • Open Access

    Safety and Effectiveness of an Integrative Treatment of Acupuncture-Based Intervention in Survivors of Breast Cancer With Postmastectomy Pain Syndrome: Protocol for a Single-Center, Single-Arm Exploratory Trial

    by Naruaki Kawasaki, Hiroto Ishiki, Naho Matsubara, Takako Ikegami, Ayaka Ishikawa, Sayaka Arakawa, Asuka Takahashi, Tomoko Uchida, Yukie Nameki, Yoko Horiguchi, et al.

    Background: Postmastectomy pain syndrome (PMPS) is a prevalent chronic pain condition that occurs after breast cancer surgery, often impairing quality of life in survivors of breast cancer. Despite its prevalence, no standardized treatment has been established. Acupuncture has been reported to be an efficacious intervention for the management of chronic pain and may be an effective treatment for PMPS. Objective: This study aims to explore the effectiveness and safety of integrative treatment of acupuncture-based intervention for PMPS. Methods: This is a single-center, single-arm, prospective interventional study. Eligible participants are patients with breast cancer who experience chronic postoperative pain in the chest, neck, or shoulder with a numerical rating scale (NRS) score ≥4, are at least 6 months postcurative treatment, have no evidence of disease recurrence, and are not receiving anticancer treatment at enrollment. Participants will receive the intervention once weekly for 12 sessions, followed by a 4-week observation period. The primary end point is the change in the average pain NRS score from baseline to week 16. Results: The study commenced in October 2023 and is scheduled to continue through March 31, 2027. The first participant was enrolled on October 24, 2023. As of the manuscript submission, 24 patients have been enrolled. Conclusions: This study will explore the potential role of an integrative treatment of acupuncture-based intervention in the management of PMPS. The results will contribute to the evidence base for acupuncture in PMPS and inform the design of future clinical studies.

  • Olanzapine Prophylaxis for Opioid-Induced Nausea and Vomiting: A Single-Arm Exploratory Study

    by Eriko Satomi, Naho Matsubara, Rumi Nishimura, Akiko Abe, Naruaki Kawasaki, Sayaka Arakawa, Hiroto Ishiki, Koji Amano, Naomi Sakiyama, Keisuke Ariyoshi, et al.


  • Open Access

    Impact of segmentectomy on treatment for secondary malignancies and other causes of death after lung cancer surgery

    by Naruaki Kawasaki, Yukihiro Yoshida, Masaya Yotsukura, Tomohiro Haruki, Hirokazu Watanabe, Ryo Sadachi, Shun-Ichi Watanabe


  • Effect of Acupuncture on Neurogenic Claudication Among Patients With Degenerative Lumbar Spinal Stenosis

    by Naruaki Kawasaki, Hiroto Ishiki, Sayaka Arakawa, Yoko Horiguchi, Eriko Satomi

  • Myofascial pain syndrome in patients with cancer: a narrative review

    by Naruaki Kawasaki, Hiroto Ishiki, Sayaka Arakawa, Eriko Satomi, Hiromichi Matsuoka, Hideaki Hasuo

    Purpose Myofascial pain syndrome (MPS) is a chronic musculoskeletal pain syndrome. The purpose of this review is to describe the epidemiological and treatment evidence and to address the future research agenda in patients with cancer. Methods A narrative review of previous reports investigating the prevalence and treatment of MPS in the oncology field is presented. The target population is patients with cancer and cancer survivors. Results There have been three prospective and two retrospective studies investigating the prevalence of MPS. MPS is as high as 38%–45% in patients with advanced or incurable cancer and 11.9%–44.8% in cancer survivors. A total of nine reports investigated the efficacy of the following interventions: trigger point injection (TPI), myofascial techniques and ischaemic compression. TPI has been reported to be effective in four observational studies. One randomised study reported the efficacy of myofascial techniques, but two randomised studies reported no added beneficial effects of it in breast cancer survivors. Two randomised studies investigated the efficacy of ischaemic compression, but the obtained results were contradictory. Conclusions MPS is highly prevalent. We should know that non-cancer pain is also common in both patients with cancer and survivors. In treating such pain, careful physical examination is essential. Then, non-pharmacological treatment should be considered as well as pharmacotherapy. As evidence regarding MPS in the oncology field is scarce, further research is warranted.


  • Pain, Analgesic Use, and Patient Satisfaction With Spinal Versus General Anesthesia for Hip Fracture Surgery

    by Yu Toda, Hiroto Ishiki, Taku Machida, Naruaki Kawasaki, Eisuke Kobayashi